Drug Search Results
More Filters [+]

Remimazolam

Alternative Names: remimazolam, cns 7056, byfavo
Latest Update: 2024-09-06
Latest Update Note: Clinical Trial Update

Product Description

Remimazolam, a novel benzodiazepine created out of so-called soft drug development, is an ultrashort-acting intravenous sedative-hypnotic currently being investigated in clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27496519/)

Mechanisms of Action: GABA Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Sweden | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Remimazolam

Countries in Clinic: Australia, China, Denmark, Korea, Netherlands, United States

Active Clinical Trial Count: 11

Highest Development Phases

Phase 3: Healthy Volunteers|Other

Phase 2: Anesthesia Related|COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-004118-37

P3

Active, not recruiting

Other

2025-02-28

DA10030

P3

Active, not recruiting

Other

2024-12-01

82%

HR7056-302

P3

Completed

Other

2024-08-13

NCT05836545

P3

Not yet recruiting

Healthy Volunteers

2023-12-31

Recent News Events